NextCell Pharma: 6-year ProTrans T1D data - Redeye

NextCell yesterday announced six-year follow-up data for ProTrans in type 1 diabetes, confirming that approximately 50% of endogenous insulin production is preserved six years post-treatment. The shares are up 20% since the announcement, reflecting increased confidence in investment case ahead of the important readout of ProTrans-Young in Q3 this year.

Länk till analysen i sin helhet: https://www.redeye.se/research/1144847/nextcell-pharma-6-year-protrans-t1d-data?utm_source=finwire&utm_medium=RSS